Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab.
Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab.
复制标题
免疫介导的用利妥昔单抗治疗的免疫介导的肾脏疾病患者对BNT162B2 SARS-COV-2疫苗接种的体液反应率低。
DOI：
10.1093/ckj/sfab102
复制
发表时间：
2021-09
影响因子：
4.6
通讯作者：
Morelle J
中科院分区：
文献类型：
--
作者：
Demoulin N;Scohy A;Gillion V;Godefroid N;Jadoul M;Morelle J
接受利妥昔单抗治疗的患者面临威胁生命的2019冠状病毒病（COVID-19）的高风险，强调需要有效的预防策略[1]。BNT 162 b2信使RNA疫苗（辉瑞/BioNTech）的两剂方案在95.5%的普通人群中提供了95%的COVID-19保护和体液应答[2，3]。由于利妥昔单抗消耗B细胞并损害对流感疫苗接种的反应[4，5]，预计它会改变COVID-19疫苗接种后的免疫状况。在此，我们首次研究了利妥昔单抗治疗的免疫介导的肾脏疾病患者接受两剂BNT 162 b2后的体液反应。纳入了11例连续患者（表1）。中位年龄为38岁[四分位距（IQR）36-61]，最后一次利妥昔单抗给药是在首次疫苗给药前2.4个月（IQR 1.9-4.9）。所有患者在利妥昔单抗单药治疗下均达到疾病缓解。
Patients receiving rituximab are at high risk for life-threatening coronavirus disease 2019 (COVID-19), stressing the need for effective prevention strategies [1]. A two-dose regimen of the BNT162b2 messenger RNA vaccine (Pfizer/BioNTech) confers 95% protection against COVID-19 and elicits a humoral response in 95.5% of the general population [2, 3]. Because rituximab depletes B cells and impairs response to influenza vaccination [4, 5], it is expected to alter immunization after COVID-19 vaccines.Here we investigated for the first time the humoral response after two doses of BNT162b2 in patients with immune-mediated kidney disease treated with rituximab. Eleven consecutive patients were included (Table 1). The median age was 38years [interquartile range (IQR) 36–61] and the last rituximab dose was administered 2.4 months (IQR 1.9–4.9) before the first vaccine dose. All patients were in disease remission under rituximab monotherapy.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
4.6
作者：
Westra, J.;van Assen, S.;Bijl, M.
通讯作者：
Bijl, M.
影响因子：
27.4
作者：
Strangfeld A;Schäfer M;Gianfrancesco MA;Lawson-Tovey S;Liew JW;Ljung L;Mateus EF;Richez C;Santos MJ;Schmajuk G;Scirè CA;Sirotich E;Sparks JA;Sufka P;Thomas T;Trupin L;Wallace ZS;Al-Adely S;Bachiller-Corral J;Bhana S;Cacoub P;Carmona L;Costello R;Costello W;Gossec L;Grainger R;Hachulla E;Hasseli R;Hausmann JS;Hyrich KL;Izadi Z;Jacobsohn L;Katz P;Kearsley-Fleet L;Robinson PC;Yazdany J;Machado PM;COVID-19 Global Rheumatology Alliance
通讯作者：
COVID-19 Global Rheumatology Alliance
影响因子：
27.4
作者：
Oren, S.;Mandelboim, M.;Elkayam, O.
通讯作者：
Elkayam, O.
DOI：
10.1016/j.cmi.2021.05.004
发表时间：
2021-09
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Favresse J;Bayart JL;Mullier F;Dogné JM;Closset M;Douxfils J
通讯作者：
Douxfils J